IL166466A0 - Methods for the treatment of dementia based on apoe genotype - Google Patents

Methods for the treatment of dementia based on apoe genotype

Info

Publication number
IL166466A0
IL166466A0 IL16646605A IL16646605A IL166466A0 IL 166466 A0 IL166466 A0 IL 166466A0 IL 16646605 A IL16646605 A IL 16646605A IL 16646605 A IL16646605 A IL 16646605A IL 166466 A0 IL166466 A0 IL 166466A0
Authority
IL
Israel
Prior art keywords
methods
treatment
apoe genotype
dementia based
dementia
Prior art date
Application number
IL16646605A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL166466A0 publication Critical patent/IL166466A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775Apolipopeptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
IL16646605A 2002-08-07 2005-01-24 Methods for the treatment of dementia based on apoe genotype IL166466A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40169402P 2002-08-07 2002-08-07
PCT/EP2003/008719 WO2004015140A1 (en) 2002-08-07 2003-08-06 Methods for the treatment of dementia based on apo e genotype

Publications (1)

Publication Number Publication Date
IL166466A0 true IL166466A0 (en) 2006-01-15

Family

ID=31715721

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16646605A IL166466A0 (en) 2002-08-07 2005-01-24 Methods for the treatment of dementia based on apoe genotype

Country Status (14)

Country Link
US (3) US20060160079A1 (zh)
EP (1) EP1529116B1 (zh)
JP (1) JP2005534710A (zh)
CN (1) CN1681941A (zh)
AT (1) ATE435302T1 (zh)
AU (1) AU2003266967B2 (zh)
BR (1) BR0313588A (zh)
CA (1) CA2494585A1 (zh)
DE (1) DE60328198D1 (zh)
DK (1) DK1529116T3 (zh)
ES (1) ES2327914T3 (zh)
IL (1) IL166466A0 (zh)
PT (1) PT1529116E (zh)
WO (1) WO2004015140A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
WO2006014755A2 (en) * 2004-07-20 2006-02-09 Wyeth Methods of identifying patients at risk of developing encephalitis following immunotherapy for alzheimer’s disease
US20060228728A1 (en) * 2005-01-31 2006-10-12 Perlegen Sciences, Inc. Genetic basis of Alzheimer's disease and diagnosis and treatment thereof
US7740593B2 (en) 2005-12-09 2010-06-22 Senorx, Inc Guide block for biopsy or surgical devices
ES2556535T3 (es) 2007-07-31 2016-01-18 Accera, Inc. Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
AU2009266869B2 (en) 2008-07-03 2016-07-07 Cerecin Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
CN110891417B (zh) 2017-03-21 2023-05-23 杰克逊实验室 表达人APOE4和小鼠Trem2 p.R47H的遗传修饰小鼠及其使用方法
PT3630098T (pt) 2017-05-24 2021-04-21 H Lundbeck As Combinação de um antagonista do receptor 5-ht6 e de um inibidor de acetilcolinesterase para utilização no tratamento da doença de alzheimer numa subpopulação de pacientes portadores de alelos apoe4
EP3809838A4 (en) * 2018-06-21 2022-03-23 The Jackson Laboratory GENETICALLY MODIFIED MOUSE MODELS OF ALZHEIMER'S DISEASE
US20220127680A1 (en) * 2019-02-28 2022-04-28 The Rockefeller Universtiy Apoe genotyping in cancer prognostics and treatment
CN114728875A (zh) 2019-12-13 2022-07-08 因思博纳公司 金属盐及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0625212B1 (en) * 1992-10-13 2004-03-24 Duke University Methods of detecting alzheimer's disease
CA2111503A1 (en) * 1993-12-15 1995-06-16 Mcgill University Apolipoprotein e polymorphism and alzheimer's disease
FR2765591B1 (fr) * 1997-07-01 2002-08-09 Pasteur Institut Procede de diagnostic de la maladie d'alzheimer
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
JP2000069963A (ja) * 1998-08-31 2000-03-07 Igaku Seibutsugaku Kenkyusho:Kk アポリポプロテインe4特異モノクローナル抗体
NZ510683A (en) * 1998-10-01 2003-09-26 Novartis Ag Sustained release oral formulations of rivastigmine
ATE314343T1 (de) * 2000-06-30 2006-01-15 Elan Pharm Inc Verbindungen zur behandlung der alzheimerischen krankheit

Also Published As

Publication number Publication date
CN1681941A (zh) 2005-10-12
US20080214662A1 (en) 2008-09-04
US20100240744A1 (en) 2010-09-23
ATE435302T1 (de) 2009-07-15
DK1529116T3 (da) 2009-11-09
BR0313588A (pt) 2005-07-12
US20060160079A1 (en) 2006-07-20
EP1529116B1 (en) 2009-07-01
EP1529116A1 (en) 2005-05-11
PT1529116E (pt) 2009-09-10
ES2327914T3 (es) 2009-11-05
JP2005534710A (ja) 2005-11-17
WO2004015140A1 (en) 2004-02-19
CA2494585A1 (en) 2004-02-19
DE60328198D1 (de) 2009-08-13
AU2003266967A1 (en) 2004-02-25
AU2003266967B2 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
IL166466A0 (en) Methods for the treatment of dementia based on apoe genotype
NL301145I1 (zh)
WO2006002262A3 (en) Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
SG147442A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
MX2007009565A (es) Metodos y reactivos para tratamiento y diagnostico de degeneracion macular relacionada con la edad.
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
HK1069767A1 (en) Methods for inhibiting ocular processes
PT1938839E (pt) Composições oftálmicas de estimulantes parassimpáticos e anti-inflamatórios para utilização no tratamento de presbiopia
TW200716141A (en) Compositions and methods for treatment for neoplasms
HK1166465A1 (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as parp inhibitors for use in treating cancer
MY143215A (en) Multifocal lenses for pre-presbyopic individuals
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2007047608A3 (en) Fibrin targeted therapeutics
DE602005021889D1 (en) Substituierte thienopyrrolcarbonsäureamide, pyrrolothiazolcarbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i-epsilon
TW200744567A (en) Phenylethylamine analogs and their use for treating glaucoma
PL1730315T3 (pl) Polimorfizmy w genie NOD2/CARD15
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
WO2003070082A3 (en) Association of snps in the comt locus and neighboring loci with schizophrenia, bipolar disorder, breast cancer and colorectal cancer
MX2007005526A (es) Tratamiento de mastitis con enrofloxacino.
TW200510398A (en) Novel compounds
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
MX2020002008A (es) Tratamientos antivirales intravenosos.